Loading...
Vaxcyte, Inc.
PCVX•NASDAQ
Healthcare
Biotechnology
$36.63
$0.39(1.08%)
Vaxcyte, Inc. (PCVX) Financial Performance & Income Statement Overview
Review Vaxcyte, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
0.00%
Operating Income Growth
-21.69%
↓ 21.69%
Net Income Growth
-15.33%
↓ 15.33%
Operating Cash Flow Growth
-52.51%
↓ 52.51%
Operating Margin
0.00%
Gross Margin
0.00%
Net Profit Margin
0.00%
ROE
-17.12%
↓ 17.12%
ROIC
-19.38%
↓ 19.38%
Vaxcyte, Inc. (PCVX) Income Statement & Financial Overview
Review Vaxcyte, Inc.'s (PCVX) income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $4.50M | $3.48M |
| Gross Profit | $0.00 | $0.00 | -$4.50M | -$3.48M |
| Gross Profit Ratio | ||||
| R&D Expenses | $148.13M | $133.61M | $116.94M | $131.51M |
| SG&A Expenses | $32.66M | $28.55M | $22.99M | $18.00M |
| Operating Expenses | $180.79M | $162.17M | $139.92M | $149.50M |
| Total Costs & Expenses | $180.79M | $162.17M | $139.92M | $152.98M |
| Interest Income | $32.94M | $36.46M | $28.06M | $23.81M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $4.87M | $4.79M | $0.00 | $3.48M |
| EBITDA | -$175.92M | -$52.58M | -$139.92M | -$152.98M |
| EBITDA Ratio | ||||
| Operating Income | -$180.79M | -$162.17M | -$139.92M | -$152.98M |
| Operating Income Ratio | ||||
| Other Income/Expenses (Net) | $40.08M | $25.09M | $36.80M | $24.28M |
| Income Before Tax | -$140.72M | -$137.08M | -$103.12M | -$128.70M |
| Income Before Tax Ratio | ||||
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$140.72M | -$137.08M | -$103.12M | -$128.70M |
| Net Income Ratio | ||||
| EPS | -$1.04 | -$1.12 | -$0.83 | -$1.10 |
| Diluted EPS | -$1.04 | -$1.12 | -$0.83 | -$1.10 |
| Weighted Avg Shares Outstanding | $135.69M | $122.85M | $123.69M | $117.26M |
| Weighted Avg Shares Outstanding (Diluted) | $135.69M | $122.85M | $123.69M | $117.26M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan